Afimoxifene clinical trials
Also written 4-hydroxytamoxifen and 4-OHT.
How each study uses afimoxifene is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2009 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 6
Northwestern University (4) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · BHR Pharma, LLC (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Estrogen Antagonists source
- One of SERMs source
Studies
Open first, then newest update. How each study uses afimoxifene is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer RiskTerminatedPhase 2Mayo ClinicNCT04570956Written as Topical 4-OHT( 4-hydroxytamoxifen)gel 4 mg/each breast/day
- Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One BreastActive, not recruitingPhase 2Northwestern UniversityNCT04009044Written as Afimoxifene
- Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the BreastCompletedPhase 2Northwestern UniversityNCT02993159Written as Afimoxifene
- Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense BreastCompletedPhase 2M.D. Anderson Cancer CenterNCT03063619Written as Afimoxifene
- Trial of 4-Hydroxytamoxifen (4-OHT) Gel in Women Aimed at Reducing Dense Breast TissueTerminatedPhase 3BHR Pharma, LLCNCT03199963Written as 4-OH tamoxifen
- 4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in SituCompletedPhase 2Northwestern UniversityNCT00952731Written as afimoxifene
- Effect of 4-Hydroxytamoxifen Gel on Breast Density, Salivary Sex Steroids, and Quality of Life in Premenopausal WomenCompletedNot applicableNorthwestern UniversityNCT00084344Written as 4-hydroxytamoxifen
Codes
What other systems call afimoxifene · ClinicalTrials.gg INT002656
- MeSH (NLM) C016601afimoxifeneConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 17197F0KYMAFIMOXIFENEConfirmed FDA, NLM
- NCI Thesaurus C975AfimoxifeneOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C016601 | afimoxifene | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 17197F0KYM | AFIMOXIFENE | Confirmed FDA, NLM |
| NCI Thesaurus | C975 | Afimoxifene | One source FDA |
Also registered as hydroxytamoxifen (UNII 95K54647BZ).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.